The association of V249I and T280M fractalkine receptor haplotypes with disease course of multiple sclerosis

Journal of Neuroimmunology

Volumn 245, Issue 1-2, 2012, Pages 87-92

  Stojković, Ljiljana ^a   Djurić, Tamara ^a   Stanković, Aleksandra ^a   Dinčić, Evica ^b   Stančić, Olja ^a   Veljković, Nevena ^a   Alavantić, Dragan ^a   Živković, Maja ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF DEFENCE   (Serbia)

Author keywords

Clinical course; CX3CR1; Haplotypes; Multiple sclerosis; Polymorphism; T280M; V249I

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE;

ADULT; ALLELE; AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN INTERACTION;

ADULT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; ISOLEUCINE; MALE; METHIONINE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POLYMORPHISM, GENETIC; RECEPTORS, CHEMOKINE; THREONINE; VALINE;

EID: 84859637639     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.12.028     Document Type: Article

References (35)

1. Apostolakis S., Amanatidou V., Papadakis E.G., Spandidos D.A. Genetic diversity of CX3CR1 gene and coronary artery disease: new insights through a meta-analysis. Atherosclerosis 2009, 207:8-15.
2. Apostolakis S., Baritaki S., Kochiadakis G.E., Igoumenidis N.E., Panutsopulos D., Spandidos D.A. Effects of polymorphisms in chemokine ligands and receptors on susceptibility to coronary artery disease. Thromb. Res. 2007, 119:63-71.
3. Balashov K.E., Rottman J.B., Weiner H.L., Hancock W.W. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1 alpha and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:6873-6878.
4. Bazan J.F., Bacon K.B., Hardiman G., Wang W., Soo K., Rossi D., Greaves D.R., Zlotnik A., Schall T.J. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997, 385:640-644.
5. Carter K.W., McCaskie P.A., Palmer L.J. JLIN: a java based linkage disequilibrium plotter. BMC Bioinformatics 2006, 7:60.
6. Chan C.C., Tuo J., Bojanowski C.M., Csaky K.G., Green W.R. Detection of CX3CR1 single nucleotide polymorphism and expression on archived eyes with age-related macular degeneration. Histol. Histopathol. 2005, 20:857-863.
7. Combadière C., Godin O., Vidal C., Cangialosi A., Proust C., Tzourio C. Common CX3CR1 alleles are associated with a reduced risk of headaches. Headache 2008, 48:1061-1066.
8. Compston A., Coles A. Multiple sclerosis. Lancet 2002, 359:1221-1231.
9. Daoudi M., Lavergne E., Garin A., Tarantino N., Debré P., Pincet F., Combadière C., Deterre P. Enhanced adhesive capacities of the naturally occuring Ile249-Met280 variant of the chemokine receptor CX3CR1. J. Biol. Chem. 2004, 279:19649-19657.
10. de Bakker P.I.W., Yelensky R., Pe'er I., Gabriel S.B., Daly M.J., Altshuler D. Efficiency and power in genetic association studies. Nat. Genet. 2005, 37:1217-1223.
11. Dupont W.D., Plummer W.D. Power and sample size calculations: a review and computer program. Control. Clin. Trials 1990, 11:116-128.
12. Faure S., Meyer L., Costagliola D., Vaneensberghe C., Genin E., Autran B., Delfraissy J.F., McDermott D.H., Murphy P.M., Debré P., Théodorou I., Combadière C. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 2000, 287:2274-2277.
13. Ghilardi G., Biondi M.L., Turri O., Guagnellini E., Scorza R. Internal carotid artery occlusive disease and polymorphisms of fractalkine receptor CX3CR1: a genetic risk factor. Stroke 2004, 35:1276-1279.
14. Hulshof S., Van Haastert E.S., Kuipers H.F., Van Den Elsen P.J., De Groot C.J., Van Der Valk P., Ravid R., Biber K. CX3CL1 and CX3CR1 expression in human brain tissue: noninflammatory control versus multiple sclerosis. J. Neuropathol. Exp. Neurol. 2003, 62:9.
15. Imai T., Hieshima K., Haskell C., Baba M., Nagira M., Nishimura M., Kakizaki M., Takagi S., Nomiyama H., Schall T.J., Yoshie O. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997, 91:521-530.
16. Infante-Duarte C., Weber A., Krätzschmar J., Prozorovski T., Pikol S., Hamann I., Bellmann-Strobl J., Aktas O., Dörr J., Wuerfel J., Stürzebecher C.S., Zipp F. Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients. FASEB J. 2005, 19:1902-1904.
17. International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219.
18. Kimouli M., Miyakis S., Georgakopoulos P., Neofytou E., Achimastos A.D., Spandidos D.A. Polymorphisms of fractalkine receptor CX3CR1 gene in patients with symptomatic and asymptomatic carotid artery stenosis. J. Atheroscler. Thromb. 2009, 16:604-610.
19. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
20. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in multiple sclerosis. Neurology 1996, 46:907-911.
21. Matzhold E.M., Trummer O., Grünbacher G., Zulus B., Boehm B.O., März W., Renner W. Association of polymorphisms in the chemokine receptor CX3CR1 gene with coronary artery disease. Cytokine 2009, 47:224-227.
22. McDermott D.H., Fong A.M., Yang Q., Sechler J.M., Cupples L.A., Merrell M.N., Wilson P.W., D'Agostino R.B., O'Donnell C.J., Patel D.D., Murphy P.M. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J. Clin. Invest. 2003, 111:1241-1250.
23. McDermott D.H., Halcox J.P., Schenke W.H., Waclawiw M.A., Merrell M.N., Epstein N., Quyyumi A.A., Murphy P.M. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ. Res. 2001, 89:401-407.
24. Menashe I., Rosenberg P.S., Chen B.E. PGA: power calculator for case-control genetic association analyses. BMC Genet. 2008, 9:36.
25. Moatti D., Faure S., Fumeron F., Amara M.W., Seknadji P., McDermott D.H., Debré P., Aumont M.C., Murphy P.M., de Prost D., Combadière C. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 2001, 97:1925-1928.
26. Norata G.D., Garlaschelli K., Ongari M., Raselli S., Grigore L., Catapano A.L. Effects of fractalkine receptor variants on common carotid artery intima-media thickness. Stroke 2006, 37:1558-1561.
27. Piccio L., Rossi B., Scarpini E., Laudanna C., Giagulli C., Issekutz A.C., Vestweber D., Butcher E.C., Constantin G. Molecular mechanisms involved in lymphocyte recruitment in inflamed brain microvessels: critical roles for P-selectin glycoprotein ligand-1 and heterotrimeric G(i)-linked receptors. J. Immunol. 2002, 168:1940-1949.
28. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O'Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302.
29. Roxburgh R.H., Seaman S.R., Masterman T., Hensiek A.E., Sawcer S.J., Vukusic S., Achiti I., Confavreux C., Coustans M., le Page E., Edan G., McDonnell G.V., Hawkins S., Trojano M., Liguori M., Cocco E., Marrosu M.G., Tesser F., Leone M.A., Weber A., Zipp F., Miterski B., Epplen J.T., Oturai A., Sorensen P.S., Celius E.G., Lara N.T., Montalban X., Villoslada P., Silva A.M., Marta M., Leite I., Dubois B., Rubio J., Butzkueven H., Kilpatrick T., Mycko M.P., Selmaj K.W., Rio M.E., Sa M., Salemi G., Savettieri G., Hillert J., Compston D.A. Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology 2005, 64:1144-1151.
30. Sabate J.M., Ameziane N., Lamoril J., Jouet P., Farmachidi J.P., Soule J.C., Harnois F., Sobhani I., Jian R., Deybach J.C., de Prost D., Coffin B. The V249I polymorphism of the CX3CR1 gene is associated with fibrostenotic disease behavior in patients with Crohn's disease. Eur. J. Gastroenterol. Hepatol. 2008, 20:748-755.
31. Sunnemark D., Eltayeb S., Nilsson M., Wallström E., Lassmann H., Olsson T., Berg A.L., Ericsson-Dahlstrand A. CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. J. Neuroinflammation 2005, 2:17.
32. Tregouet D.A., Escolano S., Tiret L., Mallet A., Golmard J.L. A new maximum likelihood algorithm for haplotype-based association analysis: the SEM algorithm. Ann. Hum. Genet. 2004, 68:165-177.
33. Tregouet D.A., Garelle V. A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics 2007, 23:1038-1039.
34. Umehara H., Bloom E.T., Okazaki T., Nagano Y., Yoshie O., Imai T. Fractalkine in vascular biology: from basic research to clinical disease. Arteriocler. Thromb. Vasc. Biol. 2004, 24:34-40.
35. Veljkovic V., Veljkovic N., Esté J.A., Hüther A., Dietrich U. Application of the EIIP/ISM bioinformatics concept in development of new drugs. Curr. Med. Chem. 2007, 14:441-453.